Home » Topics » BioWorld Science

BioWorld Science
RSS

British Biotech discontinues development of MMP inhibitor

Dec. 9, 1996

Dusa photodynamic therapy advances to phase III

Dec. 9, 1996

Access in-licenses polymer platinum compounds

Dec. 9, 1996

InSite Vision completes preliminary clinical trial of ophthalmic drug candidate

Dec. 9, 1996

Therapeutically active NPY analog reported by academic source

Dec. 9, 1996

VIP analogs and derivatives claimed for smooth muscle relaxation

Dec. 9, 1996

New thrombin inhibitors under study at Merck & Co.

Dec. 9, 1996

Novo Nordisk claims dopamine D3 receptor ligands for CNS indications

Dec. 9, 1996

Bayer reveals sugar-modified cytostatic agents

Dec. 9, 1996

New calcimimetic agents from ZymoGenetics

Dec. 9, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...